Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

NCT05380492 is registered in ClinicalTrials.gov with Perceive Biotherapeutics, Inc. as lead sponsor.

NCT NCT05380492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05380492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Lead sponsor
Perceive Biotherapeutics, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
November 17, 2022
Completion date
November 30, 2025
Enrollment
45 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, geographic atrophy